Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R F Bergstrom

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
The British Journal of Psychiatry. Supplement|September 1, 1988
Clinical pharmacology and pharmacokinetics of fluoxetine: a reviewR F Bergstrom, L Lemberger, N A Farid, et al.
Journal of Clinical Pharmacology|August 1, 1987
Nizatidine, and H2-receptor antagonist: disposition and safety in the elderlyJ T Callaghan, A Rubin, M P Knadler, et al.
Clinical Pharmacology and Therapeutics|January 20, 1998
Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadineR F Bergstrom, M J Goldberg, B J Cerimele, et al.
Clinical Pharmacology and Therapeutics|September 1, 1981
Penicillamine kinetics in normal subjectsR F Bergstrom, D R Kay, T M Harkcom, et al.
Clinical Pharmacokinetics|October 8, 1999
Olanzapine. Pharmacokinetic and pharmacodynamic profileJ T Callaghan, R F Bergstrom, L R Ptak, et al.
Clinical Pharmacology and Therapeutics|August 1, 1997
The effect of sertraline on the pharmacokinetics of desipramine and imipramineD L Kurtz, R F Bergstrom, M J Goldberg, et al.
Clinical Pharmacology and Therapeutics|April 1, 1988
The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepamL Lemberger, H Rowe, J C Bosomworth, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Clinical pharmacokinetics of intravenously injected tritiated vinzolidineW Kreis, D R Budman, J Freeman, et al.
Clinical Pharmacology and Therapeutics|June 1, 1985
Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanolL Lemberger, H Rowe, R F Bergstrom, et al.
International Clinical Psychopharmacology|January 1, 1993
The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetineR F Bergstrom, C M Beasley, N B Levy, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
The British Journal of Psychiatry. Supplement|September 1, 1988
Clinical pharmacology and pharmacokinetics of fluoxetine: a reviewR F Bergstrom, L Lemberger, N A Farid, et al.
Journal of Clinical Pharmacology|August 1, 1987
Nizatidine, and H2-receptor antagonist: disposition and safety in the elderlyJ T Callaghan, A Rubin, M P Knadler, et al.
Clinical Pharmacology and Therapeutics|January 20, 1998
Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadineR F Bergstrom, M J Goldberg, B J Cerimele, et al.
Clinical Pharmacology and Therapeutics|September 1, 1981
Penicillamine kinetics in normal subjectsR F Bergstrom, D R Kay, T M Harkcom, et al.
Clinical Pharmacokinetics|October 8, 1999
Olanzapine. Pharmacokinetic and pharmacodynamic profileJ T Callaghan, R F Bergstrom, L R Ptak, et al.
Clinical Pharmacology and Therapeutics|August 1, 1997
The effect of sertraline on the pharmacokinetics of desipramine and imipramineD L Kurtz, R F Bergstrom, M J Goldberg, et al.
Clinical Pharmacology and Therapeutics|April 1, 1988
The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepamL Lemberger, H Rowe, J C Bosomworth, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Clinical pharmacokinetics of intravenously injected tritiated vinzolidineW Kreis, D R Budman, J Freeman, et al.
Clinical Pharmacology and Therapeutics|June 1, 1985
Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanolL Lemberger, H Rowe, R F Bergstrom, et al.
International Clinical Psychopharmacology|January 1, 1993
The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetineR F Bergstrom, C M Beasley, N B Levy, et al.
Pageof 4